Bioventus Inc. (NYSE:BVS) Shares Sold by Counterpoint Mutual Funds LLC

Counterpoint Mutual Funds LLC reduced its stake in shares of Bioventus Inc. (NYSE:BVS) by 26.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 37,645 shares of the company’s stock after selling 13,704 shares during the quarter. Counterpoint Mutual Funds LLC’s holdings in Bioventus were worth $395,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its position in shares of Bioventus by 7.5% in the third quarter. Geode Capital Management LLC now owns 940,496 shares of the company’s stock valued at $11,241,000 after purchasing an additional 65,374 shares during the last quarter. Royce & Associates LP grew its position in shares of Bioventus by 5.0% in the fourth quarter. Royce & Associates LP now owns 732,236 shares of the company’s stock valued at $7,688,000 after purchasing an additional 34,540 shares during the last quarter. State Street Corp grew its position in shares of Bioventus by 38.8% in the third quarter. State Street Corp now owns 676,501 shares of the company’s stock valued at $8,084,000 after purchasing an additional 189,216 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Bioventus by 11.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 435,344 shares of the company’s stock valued at $4,571,000 after purchasing an additional 45,182 shares during the last quarter. Finally, Segall Bryant & Hamill LLC acquired a new stake in shares of Bioventus in the third quarter valued at approximately $4,515,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Katrina J. Church sold 2,535 shares of the firm’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $10.53, for a total value of $26,693.55. Following the transaction, the senior vice president now owns 47,264 shares of the company’s stock, valued at approximately $497,689.92. This trade represents a 5.09 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Mark Leonard Singleton sold 6,498 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $66,214.62. Following the completion of the transaction, the chief financial officer now directly owns 118,817 shares in the company, valued at approximately $1,210,745.23. This represents a 5.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 52,932 shares of company stock valued at $512,511 over the last quarter. Company insiders own 32.90% of the company’s stock.

Bioventus Stock Performance

Shares of BVS opened at $9.80 on Tuesday. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The company has a market capitalization of $795.32 million, a price-to-earnings ratio of -16.07 and a beta of 0.86. The company’s 50 day simple moving average is $10.08 and its 200 day simple moving average is $11.02. Bioventus Inc. has a 1 year low of $3.90 and a 1 year high of $14.38.

Wall Street Analysts Forecast Growth

BVS has been the topic of several research reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $15.00 price target on shares of Bioventus in a research report on Monday. JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and upped their price objective for the company from $12.00 to $13.00 in a research note on Tuesday, December 17th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.